Macular degeneration (age-related) - pegaptanib and ranibizumab: Appraisal consultation (audio version)
The spoken word version of the Macular degeneration (age-related) - pegaptanib and ranibizumab: Appraisal consultation is available here in MP3 format audio files. Each section of the consultation is available as a separate file for ease of download.
To play the audio files you will need an MP3 player such as Windows media player.
If you are having difficulty accessing the files, you can download a free copy of Windows media player.
Macular degeneration (age-related) - pegaptanib and ranibizumab: Appraisal consultation (audio version) - Introduction and timetable
Macular degeneration (age-related) - pegaptanib and ranibizumab: Appraisal consultation (audio version) - Appraisal committee's recommendations
Macular degeneration (age-related) - pegaptanib and ranibizumab: Appraisal consultation (audio version) - Clinical need and practice
Macular degeneration (age-related) - pegaptanib and ranibizumab: Appraisal consultation (audio version) - The technologies
Macular degeneration (age-related) - pegaptanib and ranibizumab: Appraisal consultation (audio version) - The evidence
Macular degeneration (age-related) - pegaptanib and ranibizumab: Appraisal consultation (audio version) - Implementation
Macular degeneration (age-related) - pegaptanib and ranibizumab: Appraisal consultation (audio version) - Proposed recommendations for further research
Macular degeneration (age-related) - pegaptanib and ranibizumab: Appraisal consultation (audio version) - Related NICE guidance
Macular degeneration (age-related) - pegaptanib and ranibizumab: Appraisal consultation (audio version) - Proposed date for review guidance
Macular degeneration (age-related) - pegaptanib and ranibizumab: Appraisal consultation (audio version) - Appendix A - Appraisal committee members
Macular degeneration (age-related) - pegaptanib and ranibizumab: Appraisal consultation (audio version) - Appendix B - Sources of evidence considered by the committee
Macular degeneration (age-related) - pegaptanib and ranibizumab: Appraisal consultation (audio version) - Appendix C - Commenting on the consultation document
This page was last updated: 30 March 2010